Nature Communications (Jun 2023)

Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition

  • Mattia Zaghi,
  • Federica Banfi,
  • Luca Massimino,
  • Monica Volpin,
  • Edoardo Bellini,
  • Simone Brusco,
  • Ivan Merelli,
  • Cristiana Barone,
  • Michela Bruni,
  • Linda Bossini,
  • Luigi Antonio Lamparelli,
  • Laura Pintado,
  • Deborah D’Aliberti,
  • Silvia Spinelli,
  • Luca Mologni,
  • Gaia Colasante,
  • Federica Ungaro,
  • Jean-Michel Cioni,
  • Emanuele Azzoni,
  • Rocco Piazza,
  • Eugenio Montini,
  • Vania Broccoli,
  • Alessandro Sessa

DOI
https://doi.org/10.1038/s41467-023-39043-x
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Within the chromatin, distal elements interact with promoters to regulate specific transcriptional programs. Histone acetylation, interfering with the net charges of the nucleosomes, is a key player in this regulation. Here, we report that the oncoprotein SET is a critical determinant for the levels of histone acetylation within enhancers. We disclose that a condition in which SET is accumulated, the severe Schinzel-Giedion Syndrome (SGS), is characterized by a failure in the usage of the distal regulatory regions typically employed during fate commitment. This is accompanied by the usage of alternative enhancers leading to a massive rewiring of the distal control of the gene transcription. This represents a (mal)adaptive mechanism that, on one side, allows to achieve a certain degree of differentiation, while on the other affects the fine and corrected maturation of the cells. Thus, we propose the differential in cis-regulation as a contributing factor to the pathological basis of SGS and possibly other the SET-related disorders in humans.